{
  "url": "https://www.law.cornell.edu/regulations/new-york/9-NYCRR-113.12",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 9 § 113.12 - Manufacturing Requirements for Medical Cannabis Products",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 9 § 113.12 - Manufacturing Requirements for Medical Cannabis Products\n\nState Regulations\n(a) Requirements for extraction. Unless\notherwise approved in writing by the Office, a registered organization may only\nuse the methods, equipment, solvents, gases and mediums set forth in this\nsection when creating cannabis extracts and only in a manner exhibiting minimal\npotential for human health related toxicity. (1)\n\nAll extraction processes and activities\nmust: (i) be conducted by employees adequately\ntrained in the operation of the extraction equipment to be utilized, as well as\nthe emergency plan for incidents; (ii)\ndemonstrate control of all sources of\nignition, and occur in a spark-free environment where appropriate for the type\nof extraction method used; (iii)\nensure proper ventilation; (iv)\nhave ongoing equipment monitoring and maintain a record of regular maintenance\nof equipment based on equipment specifications; (v) follow all applicable fire, safety and\nbuilding codes, regulations, laws and guidance in the use and storage of\nsolvents, including but not limited to, maximum quantities to be held\nonsite; (vi)\nevidence the purity of\nany chemical solvents used and make any laboratory testing results or other\ndocumentation evidencing such purity and shall make such evidence readily\navailable to employees and to the office upon request. (2)\n\nUnless a registered organization obtains\nprior written approval from the Office, extraction shall only be conducted\nusing the following methods: (i) use of\nmechanical extraction methods, such as screens or presses, or heat, steam\ndistillation, ice water and other methods without employing solvents or\ngases; (ii)\nuse of a professional\ngrade, closed-loop CO2 gas extraction system that is of a supply equivalent to\nfood or beverage grade of at least 99.5 percent purity; (iii)\n\nEthanol, provided that all ethanol used\nshall be of a grade that meets or exceeds specifications of official\ncompendiums as defined in section\n321\nof Title 21 of the United States\n\nCode (USC); (iv)\nuse\nof a volatile solvent or hydrocarbon extraction method, provided that the\nmethod: (a) utilizes a commercial, professional grade closed-loop system designed to recover the\nsolvent; (b) utilizes the following\npermissible volatile solvent-based or hydrocarbon extraction substances, which\nmust be accompanied by laboratory testing results which establishes that said\nsubstances have a minimum purity level of 99 percent: (1)\n\nButane; (2)\n\nPropane; (3)\nA different volatile solvent or\nhydrocarbon with prior written approval by the Office prior to use; (c) In addition, for all proposed\nvolatile solvent based or hydrocarbon extraction, a registered organization\nshall submit to the Office, prior to receiving approval to commence extraction\noperations, documentation which demonstrates, to the satisfaction of the\n\nOffice, the following additional requirements for all designated extraction\nequipment, rooms, or other areas where volatile solvents used for extraction\nare handled or stored: (1)\nfinal certification\nletter from a licensed professional engineer or registered architect which\ncertifies the completed installation of a professionally designed, commercially\nmanufactured extraction system, that is compliant with all applicable state or\nlocal fire, safety or building codes; (2)\na letter or equivalent document as\ndetermined by the Office from the municipal jurisdiction's fire marshal, local\nbuilding code authority, or its equivalent, stating that the facility is\napproved to conduct the proposed activities and that the registered\norganization has demonstrated compliance with all applicable fire codes and/or\nregulations; and\n(3)\na certificate\nof occupancy, or equivalent document, from the local building official that all\npermits for extraction related rooms or areas have been closed as\napplicable. (b) A registered organization shall only\nproduce medical cannabis products according to the following requirements: (1)\neach medical cannabis product, in its\nfinal form, shall be defined as having a specific concentration of total\n\nTetrahydrocannabinol (THC) and total Cannabidiol (CBD) and shall have a\nconsistent phytocannabinoid profile. The concentration of the following\nphytocannabinoids, at a minimum, must be reported: (i) tetrahydrocannabinol (THC); (ii)\ntetrahydrocannabinol acid\n(THCA); (iii)\ncannabidiol\n(CBD); (iv)\ncannabinadiolic acid\n(CBDA); (v) any other marketed\nphytocannabinoid; (vi)\nany other\nphytocannabinoid component at > 0.2 percent of the phytocannabinoid profile; and\n(vii)\nterpenoid\ncontent. (2)\nthe final\nmedical cannabis product shall not contain less than ninety (90) percent, nor\nmore than 110 percent, of the concentration of total THC or total CBD, as\nindicated on the label. However: (i) where the\ntotal THC concentration is less than five (5) milligrams per dose, the\nconcentration of total THC shall be within 0.5 milligrams per dose; (ii)\nwhere the total CBD concentration is\nless than five (5) milligrams per dose, the concentration of total CBD shall be\nwithin 0.5 milligrams per dose; and\n(3)\nexcept for flower products, be\nhomogenous, with phytocannabinoid content evenly distributed throughout the\ncannabis product; unless otherwise approved by the office, the concentration of\ntotal THC and CBD in milligrams per single dose for any sample of a product\nsubmitted for testing must be within twenty-five (25) percent of the mean\nconcentration of total THC and CBD in milligrams per single dose for that\nsubmitted lot with the exception that, for products with a specified total THC\nand CBD concentration less than two (2) milligrams per single dose, the\nconcentration of each sample for that low concentration phytocannabinoid shall\nbe within 0.5 milligrams per dose of the mean concentration. (4)\nthe registered organization shall offer\nand make available to patients at least one (1) medical cannabis product that\nhas a low THC and a high CBD content (e.g., a 1:20 ratio of THC to\nCBD); (5)\nthe registered\norganization shall offer and make available at least one (1) medical cannabis\nproduct that has approximately equal amounts of THC and CBD; (6)\nfor each medical cannabis product\noffered, the registered organization shall utilize a name that complies with\nthe requirements of section\n113.12\n(j) of this\n\nPart; and\n(7)\neach registered\norganization shall have a manufacturing schedule that ensures the ability to\nproduce adequate supply of any offered medical cannabis product, unless\notherwise allowed by the Office, to ensure continuity of care for certified\npatients; (c) Excipients\nfor all forms of administration must be demonstrated safe for use in the\nproposed form. All vaporized and inhaled medical cannabis products shall meet\nthe following additional requirements: (1)\nunless prior written approval of the Office is received, medical cannabis\nvaporization devices for concentrates shall be a closed system with a\npre-filled single-use cartridge that attaches to a rechargeable battery, or a\nsingle-use product; (2)\nelectronic\nvaporization devices shall have internal or external temperature controls to\nprevent combustion and have a heating element made of inert material such as\nglass, ceramic or stainless steel and not plastic or rubber; (3)\nexcept for cannabis or hemp-derived\nterpenes, excipients and ingredients must be pharmaceutical grade unless\notherwise approved by the Office, and shall not include: (i) synthetic terpenes; (ii)\npolyethylene glycol (PEG); (iii)\nvitamin E acetate; (iv)\nmedium chain triglycerides (MCT\noil); (v) medicinal\ncompounds; (vi)\nillegal or\ncontrolled substances; (vii)\nartificial food coloring; (viii)\nbenzoic acid; (ix)\ndiketones; and\n(x) any other compound or\ningredient as determined by the Office; (4)\nnot contain any flavors or flavoring\nagents, except for cannabis-derived or hemp-derived terpenes; and\n(d) A registered organization\nshall: (1)\nuse good agricultural practices\n(GAPs); (2)\nuse good manufacturing\npractices (GMPs) and demonstrate compliance with GMP by submitting to the\n\nOffice proof of a qualified third-party GMP audit of the registered\norganization's extraction and/or manufacturing facility operations and any\nrelated certification or audit report within one year of commencing operations\nand be maintained for the duration of the registration; (3)\nconform to all applicable laws and rules\nof New York State; (4)\nuse water\nfrom a public water supply or present a plan, approved by the Office, which\ndemonstrates the ability to obtain sufficient quantities of water of equal or\ngreater quality as that from a public water supply and to monitor the quality\nof such water on an ongoing basis; (5)\nonly use pesticides that are registered\nby the New York State Department of Environmental Conservation or that\nspecifically meet the United States Environmental Protection Agency\nregistration exemption criteria for Minimum Risk Pesticides, and only in\naccordance with 6 NYCRR section 325.2(b); (6)\nprocess the leaves and flowers of the\nfemale cannabis plant only, in a safe and sanitary manner; (7)\nperform visual inspection of the\nharvested plant material to ensure there is no mold, mildew, pests, rot or gray\nor black plant material; (8)\nhave a\nseparate secure area for temporary storage of any medical cannabis or medical\ncannabis product that needs to be destroyed; and\n(9)\nprovide continual environmental\nmonitoring for temperature, ventilation and humidity at all locations in the\nmanufacturing facility where unprocessed leaf and flower material is stored, until further extraction or other processing is completed. (e) Production of any medical cannabis\nproduct shall be in accordance with general sanitary conditions. Poisonous or\ntoxic materials, including but not limited to, insecticides, rodenticides, detergents, sanitizers, caustics, acids and related cleaning compounds must be\nstored in a separate area from the cannabis and medical cannabis products in\nprominently and distinctly labeled containers, except that nothing herein\nprecludes the convenient availability of detergents or sanitizers to areas\nwhere equipment, containers and utensils are washed and sanitized. (f) Medical cannabis products shall be\nlimited to the following forms of administration: (1)\ncannabis concentrates, including, but not\nlimited to, shatters, waxes, resins and any other concentrates (not gel-based\nor water soluble); (2)\ncannabis\nedibles, including, but not limited to, capsules, beverages, tablets, tinctures, baked goods, gummies, chocolates and any other edibles; (3)\ncannabis flower products, including, but\nnot limited to, whole flower, ground flower, shake, pre-rolls, and any other\nflower; (4)\nvaporization cartridges\nor single use pens;; (5)\ntopicals; or\n(6)\nany other form approved by\nthe Board. (g) The\nregistered organization shall identify each lot of medical cannabis product\nwith a lot unique identifier. (h) The registered organization shall package the final form of the medical\ncannabis product at the manufacturing site. (1)\n\nThe original seal shall not be broken\nexcept for: (i) quality testing at an approved\nlaboratory, (ii)\nfor investigations\nor part of an inspection by the office, (iii)\nby the certified patient or designated\ncaregiver, designated caregiver facility, an authorized cannabis research\nlicense holder, or by the registered organization for internal quality control\ntesting or disposal, or\n(iv)\nby a\nregistered organization for dispensing smaller quantities of medical cannabis\nproduct to certified patients. The office may issue future guidance regarding\nthe parameters of how a registered organization may dispense smaller quantities\nof medical cannabis products to certified patients. (i) Medical Cannabis Product\n\nPackaging Minimum Standards. (1)\nA medical\ncannabis product shall: (i) be used to package\na product in its final form at the manufacturing facility; (ii)\nin addition to the packaging and\nlabeling requirements under section\n34\nof the Cannabis\n\nLaw, conform with all packaging and labeling requirements set forth in Part 128\nof this Title, except that a \"serving\" shall be referenced as a\n\"dose\"; (iii)\nbe child-resistant\nunless otherwise approved by the office; (iv)\nnotwithstanding the requirement of\nsection\n128.6\nof this Title, contain the\nmessage \"for medicinal use only\" for those dosage forms that are not authorized\nfor adult-use pursuant to article 4 of the Cannabis Law, and appliable\nregulations; and\n(v) be allowed, where the cannabis product may be used as an adult-use cannabis product or a\nmedical use product, to use a safety insert to comply with packaging and\nlabeling requirements in addition to those requirements in Part 128 of this\n\nTitle, as required by section\n34\nof the Cannabis\n\nLaw or in section\n113.13\nof this Part. (j) Medical Cannabis\n\nProduct Packaging Prohibitions. (1)\nA medical\ncannabis product shall not: (i) be opened or\nthe original seal be broken except for quality testing at an approved\nlaboratory, for adverse event investigations, by the office, by the certified\npatient or designated caregiver, designated caregiver facility, an authorized\ncannabis research license holder, or by the registered organization for\ninternal quality control testing or disposal, unless otherwise approved by the\noffice; or\n(ii)\nuse any term or\nvariants in the spelling of any term describing a medical condition. (k) Cannabis Product\n\nLabeling Minimum Standards\n(1)\n\nRegistered\norganizations shall ensure that the principal packaging display panel or safety\ninsert shall conform with all packaging and labeling requirements set forth in\n\nPart 128 of this Title and contain the following information: (i) the medical cannabis product form, and\nbrand designation; (ii)\nany other\nmarketed phytocannabinoids in milligrams per dose and milligrams per package\nshall be calculated the same way as total THC and total CBD using its acid form\nand 0.877 as part of the calculation; (iii)\nthe amount of total THC (THC + THCA x\n0.877) and any other marketed phytocannabinoids as a percentage of volume, unless otherwise exempted by the office; (2)\n\nThe information required pursuant to\nsection\n113.12\n(k)(1)\nof\nthis Part must be unobstructed and conspicuous. A registered organization may\ninclude the required information by printing the information directly onto the\nmedical cannabis package or by affixing multiple labels with the information to\nthe package, provided none of the information is obstructed. For example, and\nnot by means of limitation, the information may appear on labels that may be\naccordion, expandable, extendable, or layered to accommodate labeling of small\npackages. (m) Medical\n\nCannabis Product Labeling Prohibitions; No medical cannabis product package\nshall display any content or be labeled in any manner that: (1)\nis made attractive to individuals under\ntwenty-one (21) as set forth in section\n113.12\n(k)(1)(v)\nof\nthis Part; (2)\nincludes any false\nor misleading statements; (3)\nincludes the term \"organic\"; (4)\nincludes the term \"craft\"; (5)\ncauses a reasonable consumer confusion as to whether the medical cannabis\nproduct is trademarked, marked or labeled in a manner that violates any federal\ntrademark law or regulation; (6)\ndepicts cannabis, cannabis products, or paraphernalia; (7)\npromotes overconsumption or consumption\ncontrary to a certifying practitioner or pharmacist's recommendation; (8)\ndepicts a child or other person\nreasonably appearing to be under the age of twenty-one (21); and\n(9)\nviolates additional prohibitions as set\nout by the Office. (l) For each lot of medical cannabis product produced by the registered\norganization, a predetermined number of final medical cannabis products shall\nbe collected and submitted, in a manner approved by the Office, for final\nproduct testing to an independent laboratory/laboratories permitted by the\n\nOffice. The registered organization must review the testing results provided by\nthe independent laboratory/laboratories to verify that the concentration of\ncannabinoids is consistent with the form of medical cannabis and verify that\ncontaminants do not exceed limits, as defined by the Office, prior to the\nmedical cannabis product being released from the manufacturer to any dispensing\nsite. (m) Any lot not meeting the\nminimum testing standards for contaminants, shall be rejected and destroyed by\nthe registered organization in accordance with section\n113.25\nof this Part, except that a\nmedical cannabis product lot that has not met the minimum testing standards for\ncontaminant testing may be remediated and repurposed provided that: (1)\nthe registered organization must notify\nthe office their intention to remediated or repurposes a medical cannabis\nproduct prior to remediation initiating or repurposing process; (2)\nthe lot must be resubmitted for\nlaboratory testing in a manner set forth in section\n113.12\n(l) of this\n\nPart; (3)\nafter completing the\nrequired analyses of a representative sample obtained from a remediated or\nrepurposed medical cannabis lot, the laboratory shall report the results to the\noffice within 2 business days; (4)\na medical cannabis product lot may only be remediated or repurposed for\nextraction once. If the lot fails to meet minimum testing standards for\ncontaminants after the remediation or repurposing process, the entire lot shall\nbe destroyed by the registered organization in accordance with section\n113.25\nof this Part; (5)\nwhen a failed medical cannabis product\nlot is not remediated or reprocessed in any way it cannot be retested. Any\nsubsequent testing results produced without remediation of the failed batch\nwill not supersede the initial regulatory testing results. (6)\n\nAny lot not meeting the minimum standards\nor specifications for product consistency shall be reported to the office and\nnot dispensed by a registered organization without prior written approval from\nthe office. (7)\n\nThe registered\norganization shall keep and maintain records documenting submission of medical\ncannabis products to approved laboratories as required herein, and the results\nof the laboratory testing. The registered organization shall provide the office\nwith such records upon request. (n) The registered organization shall\ndemonstrate the stability of each medical cannabis product produced by testing\nboth the unopened and opened product in accordance with section\n113.15\n(h) of this\n\nPart: (1)\nthe stability of opened products\nshall be validated under the conditions (light, temperature and humidity), specified for storage of the product and an expiration date for opened product\nshall be determined; (2)\nthe\nstability of unopened products (e.g., sealed packages or vials) shall be\nvalidated by ongoing stability testing and an expiration date for unopened\nproducts shall be determined; (3)\nspecifications regarding storage conditions must address storage at the\nmanufacturing facility once the package is sealed, during transport, at the\ndispensing site, in the patient's home and for samples retained for future\ntesting. (o) Registered\norganization shall not prepare or produce any medical cannabis products that\ncontains: (1)\nsynthetic cannabis\nadditives; (2)\nartificially derived\nphytocannabinoid; or\n(3)\nphytocannabinoid not produced by a registered organization by extraction in an\napproved manufacturing facility. (p) In the manufacturing of medical cannabis\nproducts, a registered organization may use hemp grown pursuant to the New York\n\nState Department of Agriculture and Markets, or hemp extracts derived from\nhemp, processed or manufactured in accordance with the Office's cannabinoid\nhemp program, in accordance with applicable federal, state and local laws and\nregulations; (q) The registered\norganization's approved standard operating procedure for the aforementioned\nactivities must be followed, unless otherwise approved by the Office. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\n§\n113.12\n\nAdopted\n\nNew\n\nYork State Register February 22, 2023/Volume XLV, Issue 08, eff. 2/22/2023\n\nAmended\n\nNew\n\nYork State Register March 27, 2024/Volume XLVI, Issue 13, eff. 3/27/2024\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. (a) Requirements for extraction. Unless otherwise approved in writing by the\n\nOffice, a\nregistered organization\nmay\nonly use the methods, equipment, solvents, gases and mediums set forth in this section when creating cannabis extracts and only in a manner exhibiting minimal potential for human health related toxicity. (1)\n\nAll extraction processes and activities must: (i) be conducted by employees adequately trained in the operation of the extraction equipment to be utilized, as well as the emergency\nplan\nfor incidents; (ii)\ndemonstrate\ncontrol\nof all sources of ignition, and occur in a spark-free environment where appropriate for the type of extraction method used; (iii)\nensure proper ventilation; (iv)\nhave ongoing equipment monitoring and maintain a\nrecord\nof regular maintenance of equipment based on equipment specifications; (v) follow all applicable fire, safety and building codes, regulations, laws and guidance in the use and storage of solvents, including but not limited to, maximum quantities to be held onsite; (vi)\nevidence the purity of any chemical solvents used and make any\ncertificate of analysis\nor other documentation evidencing such purity and shall make such evidence readily available to employees and to the\n\nOffice\nupon request. (2)\n\nUnless a\nregistered organization\nobtains prior written approval from the\n\nOffice, extraction shall only be conducted using the following methods: (i) use of\nmechanical extraction\nmethods, such as screens or presses, or heat, steam distillation, ice water and other methods without employing solvents or gases; (ii)\nuse of a professional grade, closed-loop CO2 gas extraction system that is of a supply equivalent to food or beverage grade of at least 99.5 percent purity; (iii)\n\nEthanol, provided that all ethanol used shall be of a grade that meets or exceeds specifications of official compendiums as defined in section\n321\nof Title 21 of the United States Code (USC); (iv)\nuse of a volatile solvent or hydrocarbon extraction method, provided that the method: (a) utilizes a commercial, professional grade closed-loop system designed to recover the solvent; (b) utilizes the following permissible volatile solvent-based or hydrocarbon extraction substances, which must be accompanied by a\ncertificate of analysis\nwhich establishes that said substances have a minimum purity level of 99 percent: (1)\n\nButane; (2)\n\nPropane; (3)\nA different volatile solvent or hydrocarbon with prior written approval by the\n\nOffice\nprior to use; (c) In addition, for all proposed volatile solvent based or hydrocarbon extraction, a\nregistered organization\nshall submit to the\n\nOffice, prior to receiving approval to commence extraction operations, documentation which demonstrates, to the satisfaction of the\n\nOffice, the following additional requirements for all designated extraction equipment, rooms, or other areas where volatile solvents used for extraction are handled or stored: (1)\nfinal certification letter from a licensed professional engineer or registered architect which certifies the completed installation of a professionally designed, commercially manufactured extraction system, that is compliant with all applicable\nstate\nor local fire, safety or building codes; (2)\na letter or equivalent document as determined by the\n\nOffice\nfrom the municipal jurisdiction's fire marshal, local building code\nauthority, or its equivalent, stating that the facility is approved to conduct the proposed activities and that the\nregistered organization\nhas demonstrated compliance with all applicable fire codes and/or regulations; and\n(3)\na certificate of occupancy, or equivalent document, from the local building official that all permits for extraction related rooms or areas have been closed as applicable. (b) A\nregistered organization\nshall only produce medical cannabis products according to the following requirements: (1)\neach\nmedical cannabis product, in its final\nform, shall be defined as having a specific concentration of total Tetrahydrocannabinol (THC) and total Cannabidiol (CBD) and shall have a consistent\nphytocannabinoid\nprofile. The concentration of the following\nphytocannabinoids, at a minimum, must be reported: (i) tetrahydrocannabinol (THC); (ii)\ntetrahydrocannabinol acid (THCA); (iii)\ncannabidiol (CBD); (iv)\ncannabinadiolic acid (CBDA); (v) any other marketed\nphytocannabinoid; (vi)\nany other\nphytocannabinoid\ncomponent at > 0.2 percent of the\nphytocannabinoid\nprofile; and\n(vii)\nterpenoid content, if the\nregistered organization\nwill be marketing or\nadvertising\nterpenoid content, or including terpenoid content as a part of the\nmedical cannabis product\nlabeling. (2)\nthe final\nmedical cannabis product\nshall not contain less than ninety (90) percent, nor more than 110 percent, of the concentration of total THC or total CBD, as indicated on the label. However: (i) where the total THC concentration is less than five (5) milligrams per dose, the concentration of total THC shall be within 0.5 milligrams per dose; (ii)\nwhere the total CBD concentration is less than five (5) milligrams per dose, the concentration of total CBD shall be within 0.5 milligrams per dose; and\n(iii)\nunless otherwise approved by the\n\nOffice, the concentration of total THC and CBD in milligrams per single dose for any sample of a product submitted for testing must be within twenty-five (25) percent of the mean concentration of total THC and CBD in milligrams per single dose for that submitted\nlot\nwith the exception that, for products with a specified total THC and CBD concentration less than two (2) milligrams per single dose, the concentration of each sample for that low concentration\nphytocannabinoid\nshall be within 0.5 milligrams per dose of the mean concentration. (3)\nthe\nregistered organization\nshall offer and make available to patients at least one (1)\nmedical cannabis product\nthat has a low THC and a high CBD content (e.g., a 1:20 ratio of THC to CBD); (4)\nthe\nregistered organization\nshall offer and make available at least one (1)\nmedical cannabis product\nthat has approximately equal amounts of THC and CBD; (5)\nfor each\nmedical cannabis product\noffered, the\nregistered organization\nshall utilize a name that complies with the requirements of section\n113.12\n(k) of this Part; and\n(6)\neach\nregistered organization\nshall have a\nmanufacturing\nschedule that ensures the ability to produce adequate supply of any offered\nmedical cannabis product, unless otherwise allowed by the\n\nOffice, to ensure continuity of care for certified patients; (c) Excipients for all forms of administration must be demonstrated safe for use in the proposed\nform. All vaporized and inhaled medical cannabis products shall meet the following additional requirements: (1)\nunless prior written approval of the\n\nOffice\nis received, medical cannabis vaporization devices for concentrates shall be a closed system with a pre-filled single-use cartridge that attaches to a rechargeable battery, or a single-use product; (2)\nelectronic vaporization devices shall have internal or external temperature controls to prevent combustion and have a heating element made of inert material such as glass, ceramic or stainless steel and not plastic or rubber; (3)\nexcept for cannabis or hemp-derived terpenes, excipients and ingredients must be pharmaceutical grade unless otherwise approved by the\n\nOffice, and shall not include: (i) synthetic terpenes; (ii)\npolyethylene glycol (PEG); (iii)\nvitamin E acetate; (iv)\nmedium chain triglycerides (MCT oil); (v) medicinal compounds; (vi)\nillegal or controlled substances; (vii)\nartificial food coloring; (viii)\nbenzoic acid; (ix)\ndiketones; and\n(x) any other compound or ingredient as determined by the\n\nOffice; (4)\nnot contain any flavors or flavoring agents, except for cannabis-derived or hemp-derived terpenes; and\n(d) A\nregistered organization\nshall: (1)\nuse good agricultural practices (GAPs); (2)\nuse good\nmanufacturing\npractices (GMPs) and demonstrate compliance with GMP by submitting to the\n\nOffice\nproof of a qualified third-party GMP audit of the\nregistered organization\n's extraction and/or\nmanufacturing\nfacility operations and any related certification or audit report within one year of commencing operations and be maintained for the duration of the registration; (3)\nconform to all applicable laws and rules of New York\n\nState; (4)\nuse water from a public water supply or present a\nplan, approved by the\n\nOffice, which demonstrates the ability to obtain sufficient quantities of water of equal or greater quality as that from a public water supply and to monitor the quality of such water on an ongoing basis; (5)\nonly use pesticides that are registered by the New York\n\nState\n\nDepartment\nof Environmental Conservation or that specifically meet the United States Environmental Protection\n\nAgency\nregistration exemption criteria for Minimum Risk Pesticides, and only in accordance with 6 NYCRR section 325.2(b); (6)\nprocess the leaves and flowers of the female cannabis plant only, in a safe and sanitary manner; (7)\nperform visual inspection of the harvested plant material to ensure there is no mold, mildew, pests, rot or gray or black plant material; (8)\nhave a separate secure\narea\nfor temporary storage of any medical cannabis or\nmedical cannabis product\nthat needs to be destroyed; and\n(9)\nprovide continual environmental monitoring for temperature, ventilation and humidity at all locations in the\nmanufacturing\nfacility where unprocessed leaf and flower material is stored, until further extraction or other\nprocessing\nis completed. (e) Production of any\nmedical cannabis product\nshall be in accordance with general sanitary conditions. Poisonous or toxic materials, including but not limited to, insecticides, rodenticides, detergents, sanitizers, caustics, acids and related cleaning compounds must be stored in a separate\narea\nfrom the cannabis and medical cannabis products in prominently and distinctly labeled containers, except that nothing herein precludes the convenient availability of detergents or sanitizers to areas where equipment, containers and utensils are washed and sanitized. (f) Medical cannabis products shall be limited to the following forms of administration: (1)\nmetered liquid or oil preparations; (2)\nsolid and semisolid preparations (e.g. capsules, chewable and effervescent tablets, lozenges); (3)\nmetered ground plant preparations; (4)\nwhole flower; (5)\ntopical forms and transdermal patches; or\n(6)\nany other\nform\napproved by the\n\nBoard. (g) Medical cannabis\nmay\nnot be incorporated into food or beverage products by the\nregistered organization, unless approved by the\n\nBoard\n(h) The\nregistered organization\nshall identify each\nlot\nof\nmedical cannabis product\nwith a\nlot\nunique identifier. (i) The\nregistered organization\nshall package the final\nform\nof the\nmedical cannabis product\nat the\nmanufacturing\nsite. The original seal shall not be broken except for quality testing at an approved laboratory, for\nadverse event\ninvestigations, by the\n\nOffice, by the\ncertified patient\nor designated caregiver, designated caregiver facility, an authorized cannabis research\nlicense\nholder, or by the\nregistered organization\nfor internal quality\ncontrol\ntesting or disposal. (j) Medical Cannabis Product\n\nPackaging Minimum Standards. (1)\nA\nmedical cannabis product\npackage shall: (i) be packaged and labeled in its final\nform\nat the\nmanufacturing\nfacility; (ii)\nbe easily readable and firmly affixed to the package; (iii)\nbe\nchild-resistant\nunless otherwise approved by the\n\nOffice; (iv)\nbe\ntamper-evident; (v) fully enclose the product, minimize oxygen exposure and prevent the contamination and/or degradation of the\nmedical cannabis product; and\n(vii)\nnot impart any toxic or deleterious substance onto the\nmedical cannabis product. (2)\n\nUnless otherwise approved by the\n\nOffice, a\nregistered organization\nshall maintain a copy of the certificate showing that each medical cannabis package into which the\nregistered organization\nplaces medical cannabis products is\nchild-resistant\nand complies with the requirements of 16 CFR §\n1700.15\nfor Poison Prevention Packaging Standards and 16 CFR §\n1700.20\nfor Testing Procedure for Special Packaging. (3)\n\nAn\nexit package\nis optional and is not required to be labeled but\nmay\ninclude the\nregistered organization\n's name or logo, provided that the name or logo complies with the provisions of subdivision\n113.12\n(k) of this section. (4)\n\nRegistered organizations shall implement a recycling\nprogram\nfor\nmedical cannabis product\npackaging. (5)\n\nClaims about recyclable or recycled content packaging shall comply with Title 16 of the Code of Federal Regulations relating to Commercial Practices, Part 260 regarding Guides for the Use of Environmental Marketing Claims. (k) Medical Cannabis Product\n\nPackaging Prohibitions. (1)\nA\nmedical cannabis product\npackage shall not: (i) be opened or the original seal be broken except for quality testing at an approved laboratory, for\nadverse event\ninvestigations, by the\n\nOffice, by the\ncertified patient\nor designated caregiver, designated caregiver facility, an authorized cannabis research\nlicense\nholder, or by the\nregistered organization\nfor internal quality\ncontrol\ntesting or disposal, unless otherwise approved by the\n\nOffice; (ii)\ncontain any pictures, images, or graphics, other than what\nmay\nbe required by the\n\nBoard; (iii)\ncontain any features that emit scent or sound; (iv)\ncontain any features that change or alter a package's appearance through technology, other than for anti-counterfeiting purposes; (v) be made\nattractive to individuals under twenty-one\n(21) by using or including: (a) Cartoons; (b) Bubble-type or other cartoon-like font; (c) Bright colors that are \"neon\" in appearance; (d) Similarities to products or words that refer to products that are commonly associated with or marketed in a manner so as to be\nattractive to individuals under twenty-one\n(21), including but not limited to, any imitation of food, candy, soda, drinks, cookies, or cereal, in labeling, packaging, advertising, or marketing; (e) Terms \"candy\" or \"candies\" or variants in spelling such as \"kandy\" or \"kandeez\"; (f) Symbols, images, characters, public figures, phrases, toys, or games that are commonly used to market products to individuals under the age of twenty-one (21); or\n(g) Images of individuals who could reasonably appear to be under the age of twenty-one (21). (vi)\nuse any term or variants in the spelling of any term describing a medical\ncondition; (vii)\nbe made of single-use plastic, unless containing a minimum 25% post-consumer recycled content. The\n\nBoard\nmay\nwaive this requirement upon good cause shown; and\n(viii)\nviolate any additional requirements as set out by the\n\nOffice. (l) Cannabis Product Labeling Minimum Standards\n(1)\n\nRegistered organizations shall ensure that the\nprincipal packaging display panel\nshall have a white background with black text containing the following information: (i) the\nmedical cannabis product\nform, and brand\ndesignation; (ii)\na list of all ingredients in descending order of predominance by weight in the\nmedical cannabis product\n- both active and inactive. The ingredient list must include and separately list, in bold, any major allergens set forth in the Food Allergen Labeling and Consumer Protection\n\nAct\nof 2004, Title 21, as it relates to Food and Drugs, of the U.S. Code § 343, for misbranded food. (iii)\nmilligrams per dose of total THC (THC + THCA x 0.877), total CBD (CBD + CBDA x 0.877) content; (iv)\nmilligrams per package of total THC (THC + THCA x 0.877) and total CBD (CBD + CBDA x 0.877)\n(v) any other marketed\nphytocannabinoids\nin milligrams per dose and milligrams per package; (vi)\nthe amount of total THC (THC + THCA x 0.877) and any other marketed\nphytocannabinoids\nas a percentage of volume, unless otherwise exempted by the\n\nOffice; (vii)\nthe total quantity or volume included in the package; (viii)\nthe\nmedical cannabis product\nlot\nunique identifier (\nlot\nnumber or bar code); (ix)\nthe\ndate of expiration\nof the unopened\nmedical cannabis product\nbased on stability studies in accordance with paragraph 113.12(p)(2) of this section; (x) use by date\nonce the\nmedical cannabis product\nis opened if not included on the dispensing label pursuant to 113.12(p)(1) of this section; (xi)\nthe proper storage conditions; (xii)\nthe name, address and registration number of the\nregistered organization; (xiii)\nlanguage stating: (a) \"Keep secured at all times.\"; (b) \"\nMay\nnot be resold or transferred to another\nperson.\"; (c) \"This product might impair the ability to drive.\"; (d) \"Medical cannabis products must be kept in the original container in which they were dispensed and removed from the original container only when ready for use by the\ncertified patient.\"; (e) \"KEEP PRODUCT AWAY FROM CHILDREN (unless the\nmedical cannabis product\nis being given to the child under a\npractitioner\n's care). In case of accidental ingestion or overconsumption, contact the poison\ncontrol\nhotline 1-800-222-1222 or call 9-1-1.\"\n(f) \"This product is for medicinal use only. This product should not be consumed during pregnancy or while nursing except on the advice of the certifying\npractitioner, and in the case of a nursing parent, including the infant's pediatrician.\"; and\n(g) For topical products: \"For external use only\". (xiv)\na scannable bar code or QR code linked to a downloadable\ncertificate of analysis\nfor the\nmedical cannabis product\nor linked to a website where the\ncertificate of analysis\ncan be downloaded. A\nregistered organization\nshall provide a physical or paper\ncertificate of analysis\nwhich includes, but is not limited to, the quality, safety and clinical strength of the\nmedical cannabis product\nmanufactured or dispensed by the\nregistered organization\ndirectly to certified patients or their designated caregivers upon their request, in accordance with section\n34\nof the Cannabis\n\nLaw; (xv)\nany solvent used to produce the\nmedical cannabis product, if applicable; and\n(xvi)\nany other information required by the\n\nBoard. (2)\n\nRequired labeling on the medical cannabis package must be: (i) in text no smaller than 6-point font; (ii)\nclearly written or printed and visible to consumers; (iii)\nin Times New Roman, Calibri, Arial, or Helvetica; and\n(iv)\nin the English language. In addition to the required labeling in English, licensees\nmay\ninclude an additional, accurate foreign language translation on the package that otherwise complies with this Part. (3)\n\nThe information required pursuant to section\n113.12\n(l)(1)\nof this Part must be unobstructed and conspicuous. A\nregistered organization\nmay\ninclude the required information by printing the information directly onto the medical cannabis package or by affixing multiple labels with the information to the package, provided none of the information is obstructed. For example, and not by means of limitation, the information\nmay\nappear on labels that\nmay\nbe accordion, expandable, extendable, or layered to accommodate labeling of small packages. (4)\n\nAny research\nlicensee\nconducting research approved by the\n\nBoard\ninvolving human subjects shall comply with all packaging and labeling requirements, unless the\nlicensee\nreceives prior written approval for a waiver of specific packaging or labeling requirements in connection with any research approved by the\n\nBoard. The waiver\nmay\nextend to a\nregistered organization\nproviding medical cannabis or medical cannabis products for an approved research study. (m) Medical Cannabis Product\n\nLabeling Prohibitions; No\nmedical cannabis product\npackage shall display any content or be labeled in any manner that: (1)\nis made\nattractive to individuals under twenty-one\n(21) as set forth in section\n113.12\n(k)(1)(v)\nof this Part; (2)\nincludes any false or misleading statements; (3)\nincludes the term \"organic\"; (4)\nincludes the term \"craft\"; (5)\ncauses a reasonable consumer confusion as to whether the\nmedical cannabis product\nis trademarked, marked or labeled in a manner that violates any federal trademark\nlaw\nor regulation; (6)\ndepicts cannabis, cannabis products, or paraphernalia; (7)\npromotes overconsumption or consumption contrary to a certifying\npractitioner\nor pharmacist's recommendation; (8)\ndepicts a child or other\nperson\nreasonably appearing to be under the age of twenty-one (21); and\n(9)\nviolates additional prohibitions as set out by the\n\nOffice. (n) For each\nlot\nof\nmedical cannabis product\nproduced by the\nregistered organization, a predetermined number of final medical cannabis products shall be collected and submitted, in a manner approved by the\n\nOffice, for final product testing to an independent laboratory/laboratories permitted by the\n\nBoard. The\nregistered organization\nmust review the testing results provided by the independent laboratory/laboratories to verify that the concentration of cannabinoids is consistent with the\nform of medical cannabis\nand verify that contaminants do not exceed limits, as defined by the\n\nOffice, prior to the\nmedical cannabis product\nbeing released from the manufacturer to any dispensing\nsite. (o) Any\nlot\nnot meeting the minimum testing standards for contaminants, shall be rejected and destroyed by the\nregistered organization\nin accordance with section\n113.25\nof this Part, notwithstanding a medical\ncannabis flower product\nlot\nthat has not met the minimum testing standards for microbial testing and has passed all remaining contaminant testing. A\nregistered organization\nmay\nremediate and repurpose medical cannabis flower products provided that; (1)\nthe\nlot\nmust be resubmitted for laboratory testing in a manner set forth in section\n113.12\n(n) of this Part; (2)\nafter completing the required analyses of a representative sample obtained from a remediated or repurposed medical cannabis\nlot, the laboratory shall report the results to the\n\nOffice\nwithin two (2) business days; (3)\na medical\ncannabis flower product\nlot\nmay\nonly be remediated or repurposed for extraction once. If the\nlot\nfails to meet minimum testing standards for contaminants after the remediation or repurposing process, the entire\nlot\nshall be destroyed by the\nregistered organization\nin accordance with section\n113.25\nof this Part; (4)\nwhen a failed medical cannabis flower\nlot\nis not remediated or reprocessed in any way it cannot be retested. Any subsequent testing results produced without remediation of the failed batch will not supersede the initial regulatory testing results. (5)\n\nAny\nlot\nnot meeting the minimum standards or specifications for product consistency shall be reported to the\n\nOffice\nand not dispensed by a\nregistered organization\nwithout prior written approval from the\n\nOffice. (6)\n\nThe\nregistered organization\nshall keep and maintain records documenting submission of medical cannabis products to approved laboratories as required herein, and the results of the laboratory testing. The\nregistered organization\nshall provide the\n\nOffice\nwith such records upon request. (p) The\nregistered organization\nshall demonstrate the stability of each\nmedical cannabis product\nproduced by testing both the unopened and opened product in accordance with section\n113.15\n(i) of this Part: (1)\nthe stability of opened products shall be validated under the conditions (light, temperature and humidity), specified for storage of the product and an\nexpiration date\nfor opened product shall be determined; (2)\nthe stability of unopened products (e.g., sealed packages or vials) shall be validated by ongoing stability testing and an\nexpiration date\nfor unopened products shall be determined; (3)\nspecifications regarding storage conditions must address storage at the\nmanufacturing\nfacility once the package is sealed, during transport, at the dispensing\nsite, in the patient's home and for samples retained for future testing. (q) Registered organization\nshall not prepare or produce any medical cannabis products that contains: (1)\nsynthetic cannabis additives; (2)\nartificially derived phytocannabinoid; or\n(3)\nphytocannabinoid\nnot produced by a\nregistered organization\nby extraction in an approved\nmanufacturing\nfacility. (r) In the\nmanufacturing\nof medical cannabis products, a\nregistered organization\nmay\nuse hemp grown pursuant to the New York\n\nState\n\nDepartment\nof Agriculture and Markets, or hemp extracts derived from hemp, processed or manufactured in accordance with the\n\nOffice\n's cannabinoid hemp\nprogram, in accordance with applicable federal, state\nand local laws and regulations; (s) The\nregistered organization\n's approved standard operating procedure for the aforementioned activities must be followed, unless otherwise approved by the\n\nOffice. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\n§\n113.12\n\nAdopted\n\nNew York\n\nState\n\nRegister February 22, 2023/Volume XLV, Issue 08, eff. 2/22/2023",
  "url_type": "regulation",
  "source_index": 58048
}